Associations of gut microbiome profiles with efficacy and toxicity in CD19-targeted chimeric antigen receptor (CAR) T cell treatment

被引：0
|
作者：
Schubert, M. -L [1 ]
Blumenberg, V. [2 ]
Zamir, E. [3 ]
Schmidt, S. [3 ]
Rohrbach, R. [3 ]
Waldhoff, P. [1 ]
Bozic, D. [1 ]
von Bergwelt, M. [2 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Poeck, H. [4 ]
Schmitt, M. [1 ]
Subklewe, M. [2 ]
Stein-Thoeringer, C. [1 ,3 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Klinikum Ludwig Maximilians Univ LMU Munchen, Munich, Germany
[3] Deutsch Krebsforschungszentrum, Heidelberg, Germany
[4] Univ Klinikum Regensburg, Regensburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V372
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [31] RE-Treatment with CD19-Targeted CAR-T Cells for Relapse after CD19-CAR-T Cell Therapy
    Nishio, Nobuhiro
    Hamada, Motoharu
    Nishikawa, Eri
    Kawashima, Nozomu
    Narita, Atsushi
    Muramatsu, Hideki
    Wang, Kai
    Zheng, Huyong
    Chang, Jung-Li
    Takahashi, Yoshiyuki
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [32] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
    Gust, Juliane
    Taraseviciute, Agne
    Turtle, Cameron J.
    CNS DRUGS, 2018, 32 (12) : 1091 - 1101
  • [33] Late Effects of CD19-Targeted CAR-T Cell Therapy
    Cordeiro, Ana
    Bezerra, Evandro D.
    Hill, Joshua Aiden
    Turtle, Cameron J.
    Maloney, David G.
    Bar, Merav
    BLOOD, 2018, 132
  • [34] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
    Juliane Gust
    Agne Taraseviciute
    Cameron J. Turtle
    CNS Drugs, 2018, 32 : 1091 - 1101
  • [35] Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus
    Doglio, M.
    Ugolini, A.
    Bercher-Brayer, C.
    Camisa, B.
    Toma, C.
    Norata, R.
    Del Rosso, S.
    Greco, R.
    Ciceri, F.
    Sanvito, F.
    Casucci, M.
    Manfredi, A. A.
    Bonini, C.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [36] Antibiotic-induced gut microbiome dysbiosis associated with CAR T-cell dysfunction and immune dysregulation and patient outcomes of CD19-targeted CAR T-cell therapy
    Blumenberg, V
    Baumann, S.
    Busch, G.
    Winkelmann, M.
    Froelich, L.
    Rejeski, K.
    Dekorsy, F.
    Kunz, W. G.
    Schmidt, C.
    von Bergwelt-Baildon, M.
    Buecklein, V. L.
    Stein-Thoeringer, C.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 75 - 76
  • [37] CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
    D'Ovidio, Tyler
    Ciccolini, Kathryn
    Kalac, Matko
    Osman, Keren
    Steinberg, Amir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [38] Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy
    Ababneh, Hazim S.
    Frigault, Matthew J.
    Patel, Chirayu G.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [39] Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality
    Sutherland, Natalia M.
    Zhou, Baijun
    Zhang, Lingxiao
    Ong, Mei-Sing
    Hong, Joseph S.
    Pak, Andrew
    Liu, Katherine J.
    Frigault, Matthew J.
    Maus, Marcela V.
    Hill, Joshua A.
    Reynolds, Kerry
    Walter, Jolan E.
    Camargo Jr, Carlos A.
    Barmettler, Sara
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02)
  • [40] How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
    Hill, Joshua A.
    Seo, Susan K.
    BLOOD, 2020, 136 (08) : 925 - 935
12345